La mia nuova descrizione qui!
Price of a print issue €25.00
Sir, We have read with interest the article by Rassu et al on the use of oxidized regenerated cellulose (ORC) in oncoplastic breast surgery 1. The Authors present their early experience on breast cancer patients treated with breast-conserving surgery and reshaping procedures aided by the use of ORC. With a limited follow-up of 6 to 8 months, the Authors report improved cosmetic results while no data are presented on postoperative complication rate or on the impact of ORC in the postoperative imaging and follow-up in this new subset of patients. These two parameters should be monitored strictly when proposing the use of a new biomaterial during a surgical procedure, in order to confirm its safety. In our surgical Breast Unit, we have conducted an early experience with the use of ORC (Tabotamp fibrillar®, Johnson & Johnson; Ethicon, New Brunswick, NJ, USA) as a possible aid to reduce the risk of postoperative haematoma and infections and to improve the aesthetic outcomes in patients undergoing an oncoplastic procedures for breast cancer 2.
